PT - JOURNAL ARTICLE AU - Prudence, Mitangala Ndeba AU - Léonid, Irenge Mwana Wa Bene AU - Edgar, Musubao Tsongo AU - Bosco, Kahindo Mbeva Jean AU - Patrick, Ayonga Ndeba AU - Israël, Safari Kyembwa AU - Janvier, Kubuya Bonane AU - Edmon, Ntabe Namegabe AU - Raphaël, Kabangwa Kakongo Senga AU - Guy, Mutombo Ndongala AU - Ambroise, Jérôme AU - Gala, Jean-Luc TI - Prevalence of anti-SARS-CoV-2 antibodies in people attending the two main Goma markets in the eastern Democratic Republic of Congo AID - 10.1101/2023.02.17.23286083 DP - 2023 Jan 01 TA - medRxiv PG - 2023.02.17.23286083 4099 - http://medrxiv.org/content/early/2023/02/18/2023.02.17.23286083.short 4100 - http://medrxiv.org/content/early/2023/02/18/2023.02.17.23286083.full AB - According to official data, the Democratic Republic of the Congo (DRC) has a low prevalence of the coronavirus disease 19 (COVID-19) pandemic. The goal of this cross-sectional study was to determine the COVID-19 seroprevalence in people attending Goma’s two largest markets, Kituku and Virunga. This study was conducted between September and November 2021, overlapping by one month with another similar study carried out in a slum of Bukavu, and using the same methodology.COVID-19 unvaccinated participants (n = 796 including 454 vendors and 342 customers, 60% of whom were women) were surveyed. The median age of vendors and customers was 34.2 and 30.1 years, respectively.The crude and adjusted anti-SARS-CoV-2 antibody seroprevalence rates were 70.2% (95 % CI 66.9-73.4%) and 98.8% (95% CI 94.1-100%), respectively, with no difference between vendors and customers. COVID-19 symptoms were mild or absent in 58.9% and 41.1% of participants with anti-SARS-CoV-2 antibodies respectively. COVID-19 did not require hospitalisation for any of the seropositive participants.These findings are consistent with those reported in Bukavu. They confirm that SARS-CoV-2 spread without causing severe symptoms in densely populated settlements and markets, and suggest that many COVID-19 cases went unreported. Based on these results, relevance of an untargeted hypothetical vaccination programme in these communities should be questioned.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Belgian Cooperation Agency of the ARES (Academie de Recherche et d-Enseignement Superieur) [grant COOP-CONV-20-022] and by the PADISS (Projet d-Appui au Developpement Integre du Systeme de Sante du Nord-Kivu) in the frame of the Programme de renforcement de l-offre et developpement de l-acces aux soins de sante (PRO DS) which is funded by the European Development Fund (FED11) For this work, Mitangala Ndeba Prudence (MNP), Musubao Tsongo Edgar (MTS), and Kahindo Mbeva Jean Bosco (KMJB) were supported by the ULB Collaboration Nord Kivu, Democratic Republic of Congo (Grant Goma-Nord Kivu-2021) The funders did not play any role in the study design, collection, analysis, and interpretation of data, manuscript writing, or the decision to submit the paper for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Ethical Review Committee of the Universite Catholique de Bukavu (number UCB/CIES/NC/02312021). All participants or their guardians (in the case of children) provided written consent before enrolment. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe databases used and/or analyzed during the current study are available from the corresponding author upon request.